[ A22-111] Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to § 35a Social Code Book V
Last updated 16.01.2023
Project no.: A22-111
Commission: Commission awarded on 17.10.2022 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Airways and respiratory system
Adults and adolescents, aged 12 years and older and weighing at least 40 kg, with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19
- Patients ≥ 18 years: hint of considerable added benefit
- Patients ≥ 12 to < 18 years: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.